Information Provided By: 
Fly News Breaks for July 24, 2019
EW
Jul 24, 2019 | 07:46 EDT
Jefferies analyst Raj Denhoy raised his price target for Edwards Lifesciences to $245 from $210 saying the company in Q2 saw a "significant acceleration" in TAVR growth to 18.2% from 9.8% last quarter. TAVR is "again proving the naysayers wrong and with mitral just starting to ramp, there is more to come," Denhoy tells investors in a research note. He reiterates a Buy rating on Edwards Lifesciences.
News For EW From the Last 2 Days
There are no results for your query EW
